X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs CADILA HEALTHCARE - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES CADILA HEALTHCARE DIVIS LABORATORIES/
CADILA HEALTHCARE
 
P/E (TTM) x 31.9 16.5 192.7% View Chart
P/BV x 5.7 3.9 145.6% View Chart
Dividend Yield % 0.9 1.0 83.1%  

Financials

 DIVIS LABORATORIES   CADILA HEALTHCARE
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
CADILA HEALTHCARE
Mar-18
DIVIS LABORATORIES/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,222558 219.0%   
Low Rs784362 216.9%   
Sales per share (Unadj.) Rs153.1116.3 131.7%  
Earnings per share (Unadj.) Rs39.917.9 223.6%  
Cash flow per share (Unadj.) Rs44.623.1 192.8%  
Dividends per share (Unadj.) Rs10.003.50 285.7%  
Dividend yield (eoy) %1.00.8 131.0%  
Book value per share (Unadj.) Rs201.885.4 236.3%  
Shares outstanding (eoy) m265.471,023.74 25.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.64.0 165.7%   
Avg P/E ratio x25.125.7 97.6%  
P/CF ratio (eoy) x22.519.9 113.2%  
Price / Book Value ratio x5.05.4 92.3%  
Dividend payout %25.019.6 127.8%   
Avg Mkt Cap Rs m266,266470,664 56.6%   
No. of employees `0009.711.8 82.4%   
Total wages/salary Rs m4,68718,545 25.3%   
Avg. sales/employee Rs Th4,175.010,072.7 41.4%   
Avg. wages/employee Rs Th481.51,569.1 30.7%   
Avg. net profit/employee Rs Th1,089.31,547.7 70.4%   
INCOME DATA
Net Sales Rs m40,643119,049 34.1%  
Other income Rs m7491,132 66.2%   
Total revenues Rs m41,392120,181 34.4%   
Gross profit Rs m14,46028,475 50.8%  
Depreciation Rs m1,2335,388 22.9%   
Interest Rs m23911 2.5%   
Profit before tax Rs m13,95323,308 59.9%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,3495,644 59.3%   
Profit after tax Rs m10,60418,292 58.0%  
Gross profit margin %35.623.9 148.7%  
Effective tax rate %24.024.2 99.1%   
Net profit margin %26.115.4 169.8%  
BALANCE SHEET DATA
Current assets Rs m40,10582,005 48.9%   
Current liabilities Rs m6,59560,720 10.9%   
Net working cap to sales %82.517.9 461.2%  
Current ratio x6.11.4 450.3%  
Inventory Days Days11973 162.1%  
Debtors Days Days8198 82.1%  
Net fixed assets Rs m19,99583,703 23.9%   
Share capital Rs m5311,024 51.8%   
"Free" reserves Rs m53,04386,421 61.4%   
Net worth Rs m53,57487,445 61.3%   
Long term debt Rs m025,551 0.0%   
Total assets Rs m61,585180,653 34.1%  
Interest coverage x618.426.6 2,326.1%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.70.7 100.1%   
Return on assets %17.310.6 162.3%  
Return on equity %19.820.9 94.6%  
Return on capital %26.122.0 118.6%  
Exports to sales %00-   
Imports to sales %25.20-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m10,259NA-   
Fx inflow Rs m35,38442,683 82.9%   
Fx outflow Rs m10,39911,242 92.5%   
Net fx Rs m24,98531,441 79.5%   
CASH FLOW
From Operations Rs m11,4939,193 125.0%  
From Investments Rs m-11,372-9,737 116.8%  
From Financial Activity Rs m-93515 -18.1%  
Net Cashflow Rs m28-29 -97.9%  

Share Holding

Indian Promoters % 52.0 74.8 69.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 8.3 142.2%  
FIIs % 19.0 5.9 322.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 11.0 156.4%  
Shareholders   31,796 44,069 72.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Metal & Realty Stocks Drag(09:30 am)

Asian stock markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.1% while the Hang Seng is down 0.5%.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 16, 2018 11:49 AM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - WOCKHARDT LTD. COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS